Susanne Lewis, MD
Infectious Disease · Miami, FLNPI 1922013770
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Roche Diagnostics Corporation at 53.8% of the total. Reporting peaked in 2020 at $4,500 and has fallen 64.4% since, to $1,603 in 2025.
Across 25 payments — averaging $334.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics Corporation$5K
- Gilead$2K
- Merck$2K
- Kerecis Limited$56
- Osprey Medical Inc$49
- Oxford Immunotec USA Inc$14
Across 115 payments — averaging $16,708 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.3M
- Merck$553K
- Janssen Research & Development, LLC$31K
What the payments were for
- Consulting fees$4,50054%
- Travel & lodging$3,21138%
- Food & beverage$6608%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics Corporation | 1 | $4,500 |
| Gilead | 10 | $2,179 |
| Merck | 11 | $1,574 |
| Kerecis Limited | 1 | $56 |
| Osprey Medical Inc | 1 | $49 |
| Oxford Immunotec USA Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,371 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 35 | $138,850 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $68,503 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $58,825 |
| DovatoDolutegravir Sodium/Lamivudine | 17 | $57,835 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 14 | $55,255 |
| JulucaDolutegravir/Rilpivirine | 12 | $41,304 |
| IsentressRaltegravir Potassium | 13 | $26,011 |
| OzempicSemaglutide | 23 | $24,264 |
| Darunavir | 22 | $22,188 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $7,992 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,956 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,662 |
| Ritonavir | 15 | $1,489 |
| Gabapentin | 34 | $784 |
| Epinastine Hcl | 12 | $683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $2,179 | $262,60879 claims |
| MerckIsentress | $1,574 | $26,01113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Miami
- Douglas BrustMiami$359K
- Dushyantha JayaweeraMiami$98K
- Ricardo FrancoMiami$96K
- Lilian AbboMiami$61K
- Jorge MurilloMiami$53K
- Thomas HootonMiami$42K
- Gilberto Torres-MadrizMiami$42K
- Vanessa SilebiMiami$32K
- Hector BolivarMiami$25K
- Jose Camargo GalvisMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.